tiprankstipranks
Trending News
More News >
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Hong Kong Market

Shanghai Henlius Biotech, Inc. Class H (2696) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Shanghai Henlius Biotech, Inc. Class H

(2696)

Rating:76Outperform
Price Target:
HK$58.00
▲(15.42%Upside)
Shanghai Henlius Biotech exhibits strong financial performance with robust revenue growth and profitability improvements, supported by positive technical indicators. However, a relatively high valuation poses a risk to immediate upside potential. The lack of dividend yield is not uncommon for biotech growth stocks but may limit appeal to income investors.

Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model

Company DescriptionShanghai Henlius Biotech, Inc. Class H (2696) is a leading biopharmaceutical company specializing in the research, development, manufacture, and commercialization of monoclonal antibody (mAb) drugs and other biologics. Operating in the healthcare sector, Henlius is committed to providing high-quality, affordable biologics for patients worldwide. The company's diversified portfolio includes biosimilars, innovative biologics, and immuno-oncology drugs, with a focus on oncology, autoimmunity, and ophthalmology.
How the Company Makes MoneyShanghai Henlius Biotech generates revenue primarily through the sale of its biologic drugs, including both biosimilars and innovative biologics. The company's revenue streams are heavily reliant on its marketed products, which are distributed globally. Henlius collaborates with strategic partners worldwide to enhance its market reach and product distribution, contributing significantly to its earnings. Additionally, the company invests in research and development to expand its pipeline, aiming to bring new therapies to market and thereby increase its revenue potential. Collaboration agreements, licensing deals, and joint ventures also play a crucial role in its revenue model, enabling access to new markets and technologies.

Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview

Summary
Shanghai Henlius Biotech demonstrates robust financial performance with strong revenue and profit growth. The company has improved operational margins and cash flow, successfully turning around its profitability. However, the increased reliance on debt is a risk that needs managing.
Income Statement
82
Very Positive
Shanghai Henlius Biotech has shown a strong revenue growth trajectory with a significant increase in Total Revenue from 2019 to 2024. Gross Profit Margin has remained healthy, evidenced by a 73.1% margin in 2024. The company has successfully turned around its Net Income from a loss in previous years to a profit of 820 million in 2024, improving Net Profit Margin to 14.3%. EBIT and EBITDA margins have also improved, indicating operational efficiency gains.
Balance Sheet
75
Positive
The company maintains a moderate Debt-to-Equity Ratio of 1.21 in 2024, reflecting a balanced approach to leveraging. Return on Equity has improved to 27.2%, indicating better profitability for shareholders. However, the Equity Ratio has decreased to 28.4% in 2024, suggesting a higher reliance on debt financing compared to earlier years.
Cash Flow
78
Positive
Shanghai Henlius Biotech has shown robust improvement in Free Cash Flow, with a notable growth from negative values in earlier years to 404 million in 2024. The Operating Cash Flow to Net Income ratio of 1.51 in 2024 highlights efficient cash earnings conversion. The Free Cash Flow to Net Income ratio has also improved, indicating better cash flow management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.72B5.39B3.21B1.68B587.59M
Gross Profit4.18B3.92B2.37B1.16B405.47M
EBITDA1.15B911.33M-310.61M-671.74M-814.06M
Net Income820.47M546.02M-695.26M-984.05M-1.04B
Balance Sheet
Total Assets10.60B9.90B8.92B7.17B6.44B
Cash, Cash Equivalents and Short-Term Investments772.96M1.01B833.66M154.98M1.11B
Total Debt3.65B4.09B3.68B2.62B1.83B
Total Liabilities7.58B7.71B7.29B4.88B3.24B
Stockholders Equity3.01B2.19B1.64B2.30B3.20B
Cash Flow
Free Cash Flow404.68M36.48M-383.67M-1.04B-2.12B
Operating Cash Flow1.24B1.05B981.62M90.39M-609.58M
Investing Cash Flow-909.97M-1.00B-1.36B-1.68B-1.51B
Financing Cash Flow-643.37M144.43M858.02M648.30M995.79M

Shanghai Henlius Biotech, Inc. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price50.25
Price Trends
50DMA
42.68
Positive
100DMA
34.75
Positive
200DMA
28.31
Positive
Market Momentum
MACD
2.30
Positive
RSI
61.71
Neutral
STOCH
83.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2696, the sentiment is Positive. The current price of 50.25 is above the 20-day moving average (MA) of 48.43, above the 50-day MA of 42.68, and above the 200-day MA of 28.31, indicating a bullish trend. The MACD of 2.30 indicates Positive momentum. The RSI at 61.71 is Neutral, neither overbought nor oversold. The STOCH value of 83.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2696.

Shanghai Henlius Biotech, Inc. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
HK$27.31B30.7031.65%4.23%47.71%
60
Neutral
HK$15.14B5.55-7.43%4.78%11.72%-20.69%
57
Neutral
HK$19.90B-6.35%33.63%31.50%
54
Neutral
€30.60B-32.29%43.13%28.93%
51
Neutral
HK$33.78B-19.78%25.96%39.58%
48
Neutral
HK$26.76B-253.12%330.23%59.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2696
Shanghai Henlius Biotech, Inc. Class H
50.25
27.35
119.43%
HK:6855
Ascentage Pharma Group International
77.45
51.95
203.73%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
20.90
9.42
82.06%
HK:9969
InnoCare Pharma Ltd.
13.30
8.22
161.81%
HK:9688
Zai Lab Ltd
27.60
14.12
104.75%

Shanghai Henlius Biotech, Inc. Class H Corporate Events

Shanghai Henlius Biotech Proposes New Share Option and RSU Schemes
Jun 27, 2025

Shanghai Henlius Biotech, Inc. has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, aimed at attracting and retaining skilled personnel to drive the company’s long-term development goals. The schemes, subject to shareholder approval, are designed to align the interests of participants with shareholders through share ownership, and include conditional grants to key personnel, such as Dr. Zhu, to enhance the company’s value and stakeholder benefits.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

Shanghai Henlius Biotech Proposes Governance Amendments and Committee Appointments
Jun 27, 2025

Shanghai Henlius Biotech, Inc. has announced proposed amendments to its Articles of Association and other corporate governance measures to align with updated legal and regulatory requirements. Additionally, the company has appointed new members to its Nomination Committee, enhancing its governance structure in accordance with revised listing rules.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

Shanghai Henlius Biotech Updates Nomination Committee Terms
Jun 27, 2025

Shanghai Henlius Biotech, Inc. has announced amendments to the terms of reference for its Nomination Committee, initially established in 2019. The changes emphasize the inclusion of independent non-executive directors and gender diversity within the committee, reflecting the company’s commitment to robust governance and inclusive leadership practices.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

Shanghai Henlius Biotech Announces Board Composition and Roles
Jun 27, 2025

Shanghai Henlius Biotech, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the governance structure and strategic oversight, potentially impacting the company’s future direction and market positioning.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

Shanghai Henlius Initiates Japanese Study for Cancer Treatment
Jun 24, 2025

Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a bridging study in Japan for HANSIZHUANG, combined with chemotherapy, targeting extensive-stage small cell lung cancer. This study aims to support the future marketing application of HANSIZHUANG in Japan, following successful international trials. The company is advancing multiple clinical studies globally, enhancing its position in the oncology market.

Shanghai Henlius Biotech Initiates Phase 2 Study of HLX43 for Lung Cancer
Jun 10, 2025

Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.

Shanghai Henlius Biotech Gains Approval for H Share Full Circulation
Jun 9, 2025

Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.

Shanghai Henlius Biotech’s HLX22 Receives Orphan-Drug Designation from European Commission
May 26, 2025

Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.

Shanghai Henlius Initiates Clinical Study for Ipilimumab Biosimilar
May 16, 2025

Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a Phase 1/3 clinical study of its Ipilimumab biosimilar, HLX13, for the treatment of unresectable advanced hepatocellular carcinoma in mainland China. This trial aims to assess the pharmacokinetic profiles, efficacy, safety, and immunogenicity of HLX13 compared to its reference product, YERVOY. The study’s successful progression could enhance the company’s market position in the oncology biosimilar sector, potentially impacting stakeholders positively by expanding treatment options for various cancers.

Shanghai Henlius Biotech Joins MSCI Global Small Cap Indexes
May 15, 2025

Shanghai Henlius Biotech, Inc. has been included in the MSCI Global Small Cap Indexes, effective after the market close on May 30, 2025. This inclusion is significant as the MSCI Indexes are widely referenced by international investment institutions, potentially enhancing the company’s visibility and attractiveness to investors.

Shanghai Henlius Biotech Approves Key Resolutions at 2025 AGM
May 8, 2025

Shanghai Henlius Biotech, Inc. successfully held its Annual General Meeting (AGM) on May 8, 2025, where all proposed resolutions were passed with significant shareholder support. The resolutions included the approval of the company’s annual report, board work report, board of supervisors’ work report, and final accounts report for the year 2024, reflecting strong operational performance and governance.

Shanghai Henlius Partners with Sandoz for Global Commercialization of HLX13
Apr 29, 2025

Shanghai Henlius Biotech, Inc. has entered into a license agreement with Sandoz AG to commercialize its HLX13, a recombinant anti-CTLA-4 fully human monoclonal antibody injection, across the United States, 42 European countries, Japan, Australia, and Canada. This agreement includes significant financial terms, such as an upfront payment of $31 million, potential milestone payments totaling $160 million, and sales milestone payments up to $110 million, along with double-digit tiered royalties. The deal is expected to enhance Henlius’s market presence in the oncology sector, leveraging Sandoz’s commercialization capabilities in major global markets.

Shanghai Henlius Biotech Advances Phase 3 Trial for Cancer Treatment
Apr 28, 2025

Shanghai Henlius Biotech, Inc. has received approval in Germany for an international multi-center phase 3 clinical trial of its HLX22 monoclonal antibody in combination with other therapies for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s efforts to expand its clinical trials across multiple regions, potentially enhancing its market positioning and offering new treatment options for patients with these types of cancer.

Shanghai Henlius Biotech Partners with Alvogen Korea for Cancer Drug Commercialization
Apr 25, 2025

Shanghai Henlius Biotech, Inc. has entered into a license agreement with Alvogen Korea to commercialize its serplulimab injection, HANSIZHUANG, in South Korea. This agreement grants Alvogen Korea exclusive rights to market the drug for various cancers, potentially enhancing Henlius’s market presence in Asia and providing significant financial milestones and royalties.

Shanghai Henlius Begins Phase 2 Clinical Trial for Breast Cancer Treatment
Apr 17, 2025

Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 2 clinical study of their innovative product HLX22, in combination with trastuzumab deruxtecan, for treating HER2-low, HR-positive locally advanced or metastatic breast cancer in mainland China. This study aims to evaluate the efficacy and safety of this combination therapy, which has shown promising preclinical results, potentially offering a new therapeutic strategy for patients with HER2-expressing tumors.

Shanghai Henlius Biotech Announces AGM to Discuss Key Resolutions
Apr 15, 2025

Shanghai Henlius Biotech, Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 8, 2025, where shareholders will consider and approve various resolutions. These include the company’s annual report, financial accounts, profit distribution, and budget proposals for the years 2024 and 2025. Additionally, the meeting will address the re-appointment of auditors and remuneration packages. A special resolution will be considered to grant the board a mandate to issue shares, which could impact the company’s capital structure and market operations.

Shanghai Henlius Biotech Begins Clinical Trial for Innovative Cancer Treatment
Apr 9, 2025

Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG for treating advanced/metastatic solid tumors in mainland China. This trial aims to evaluate the safety and efficacy of the combination therapy, which could offer more effective and safer clinical solutions, as no similar combination therapy has been approved globally.

Shanghai Henlius Biotech’s HLX04-O Achieves Phase 3 Success in wAMD Treatment
Apr 2, 2025

Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has successfully met its primary endpoint. This development positions the company to potentially enter a market in mainland China where no bevacizumab products have yet been approved for wAMD, indicating a significant opportunity for growth and impact on stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025